XBIO Xenetic Biosciences, Inc.: Rasio rega marang prakiraan pendapatan

Simbol lan logo merek Xenetic Biosciences Inc. (XBIO)

The forward P/S trend for Xenetic Biosciences (XBIO) is based on early preclinical tests of enzyme platforms for tumor combat. The company's current potential relies on the XCART personalized T-cell therapy system, while business development is accelerating through partnerships with medical centers to enhance immunotherapy. Meanwhile, 1.20 represents a fresh level value, helping to assess market expectations for the issuer's future revenue.

Xenetic Bio - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep XBIO (periode 04.07.2022 - 17.11.2026)

Rincian analitis perusahaan Xenetic Biosciences

- data kapitalisasi saham perusahaan:
Analisis kabeh metrik perusahaan:Xenetic Biosciences, Inc. (XBIO)
Sampel barang xeneticbio.com

Xenetic Biosciences (XBIO) resilience to volatility depends on the monetization of licenses and oncology platforms, which directly impacts the market valuation of expected cash flows. Analyzing the forward P/S trend, an investor can discern the value of a unit of future revenue, where sharp spikes in the line signal the risk of low asset liquidity when attempting a rapid exit from a position during a crisis.

Pesaing wigati

Multiplikator Forward P/S ONC (BeiGene Oncology)|Multiplikator Forward P/S Halozyme Corp HALO|RVMD: Multiplikator forward rega marang pendapatan|Ascentage Pharma Group (AAPG) - Multiplikator forward rega marang pendapatan|CG Oncology Therapeutics (CGON) - Rasio rega marang prakiraan pendapatan|Prakiraan rega marang pendapatan UroGen Pharma URGN|Rasio rega marang prakiraan pendapatan Bicara Bio|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Personalis Genomics PSNL|Multiplikator Forward P/S ERAS|Rasio rega marang pendapatan sing dikarepake DCTH|Y-mAbs Therapeutics, Inc. - Multiplikator forward rega marang pendapatan|Rasio kapitalisasi marang dodolan sing dikarepake Aura Biosciences Inc (AURA)|CADL: Multiplikator forward rega marang pendapatan|Rega forward marang dodolan ARAY (Accuray Inc.)|SLS: Multiplikator Forward P/S|ACTU: Rasio rega marang pendapatan sing dikarepake|CTOR (Citius Oncology Inc.) - Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep tuhurabio.com HURA|Multiplikator Forward P/S TARA|FATE: Rega mangsa ngarep marang pendapatan|Multiplikator Forward P/S WHWK (Aadi Bioscience)|TCRX (TScan) - Rega mangsa ngarep marang pendapatan|Champions Oncology, Inc. - Multiplikator Forward P/S|Rasio kapitalisasi marang dodolan sing dikarepake XBiotech Inc XBIT|CVM: Multiplikator Forward P/S|OSTX - Rasio kapitalisasi marang dodolan sing dikarepake|Rasio rega marang prakiraan pendapatan Radiopharm Theranostics Limited|Multiplikator Forward P/S artivabio.com|Multiplikator forward rega marang pendapatan ANL (Adlai Nortye Limited)|Veru - Kapitalisasi marang prakiraan pendapatan|Tempest Therapeutics, Inc. - Multiplikator forward rega marang pendapatan|Rasio kapitalisasi marang dodolan sing dikarepake xiliotx.com (XLO)|Renovaro - Multiplikator Forward P/S|Mural Oncology (MURA) - Multiplikator forward rega marang pendapatan|KAPA: Multiplikator Forward P/S|OKUR - Rasio kapitalisasi marang dodolan sing dikarepake|Rasio rega marang prakiraan pendapatan CytoMed Therapeutics Limited|CRIS: Rega forward marang dodolan|Multiplikator Forward P/S APLM|Multiplikator Forward P/S tharimmune.com (THAR)|Advanced Biomed Corp - Multiplikator forward rega marang pendapatan|Rega forward marang dodolan GNPX|Calidi Biotherapeutics, Inc. - Multiplikator Forward P/S|Sunshine Biopharma (SBFM) - Multiplikator forward rega marang pendapatan|salariuspharma.com (SLRX) - Rasio rega marang prakiraan pendapatan|Purple Biotech Ltd. - Rega forward marang dodolan|Rasio rega marang prakiraan pendapatan AON|Multiplikator Forward P/S BeiGene Ltd.|Rasio rega marang prakiraan pendapatan Checkpoint Therapeutics, Inc. (CKPT)|Multiplikator forward rega marang pendapatan Elevation Oncology, Inc. ELEV|Multiplikator Forward P/S ICAD (iCAD Inc.)|IKNA - Multiplikator forward rega marang pendapatan|NTBL: Multiplikator forward rega marang pendapatan|viracta.com (VIRX) - Multiplikator forward rega marang pendapatan|MorphoSys (MOR) - Rasio rega marang prakiraan pendapatan|NAYA Biosciences Corp (NAYA) - Multiplikator Forward P/S|AAPGV (Ascentage) - Multiplikator Forward P/S